StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $18.72 | $18.52 | -1.07% | 0.5M |
| 05-12 | $18.33 | $18.46 | +0.71% | 0.3M |
| 05-13 | $18.25 | $19.61 | +7.45% | 0.3M |
| 05-14 | $19.41 | $21.23 | +9.38% | 0.2M |
| 05-15 | $21.00 | $19.97 | -4.90% | 0.3M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for CBIO.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q1 2025 2025-03-31 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $1.04M | $10.84M | $0.00 | $0.00 |
Operating Income | $-24.73M | $-152.63M | $-14.22M | $-17.19M |
Net Income | $-23.28M | $-23.30M | $-15.15M | $-17.87M |
EPS (Diluted) | Not available | Not available | $-0.04 | $-0.59 |
Total Assets | $199.13M | $240.29M | $5.99M | $35.62M |
Total Liabilities | $15.28M | $37.28M | $2.62M | $47.10M |
Cash & Equivalents | $189.16M | $213.19M | $22.43M | $34.77M |
Free Cash Flow OCF − CapEx | $-9.08M | $-72.45M | $-10.85M | $-6.27M |
Shares Outstanding | 27.57M | 27.56M | 64.53M | 1.02M |
Fundamentals not available for CBIO.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
What you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
CBIO is in the extended universe. We surface dollar-volume + price-change percentiles for every US-listed name, but the full 6-factor DNA breakdown (momentum, news, sentiment, flow, relative strength) is only computed on the curated 1138-name primary list.
DNA analysis is not available for this ticker.